Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ANVS

ANVS - Annovis Bio Inc Stock Price, Fair Value and News

10.18USD+0.12 (+1.19%)Delayed as of 21 Feb 2024, 01:56 pm ET
Watchlist

Market Summary

USD10.18+0.12
Delayedas of 21 Feb 2024, 01:56 pm
1.19%

ANVS Stock Price

View Fullscreen

ANVS RSI Chart

ANVS Valuation

Market Cap

103.2M

Price/Earnings (Trailing)

-2.47

Price/Sales (Trailing)

2.8K

EV/EBITDA

-2.32

Price/Free Cashflow

-3.02

ANVS Price/Sales (Trailing)

ANVS Profitability

EBT Margin

-113503.53%

Return on Equity

-626.55%

Return on Assets

-408.07%

Free Cashflow Yield

-33.14%

ANVS Fundamentals

ANVS Revenue

Revenue (TTM)

36.8K

ANVS Earnings

Earnings (TTM)

-41.7M

Earnings Growth (Yr)

-128.8%

Earnings Growth (Qtr)

-54.31%

Breaking Down ANVS Revenue

52 Week Range

8.6123.89
(Low)(High)

Last 7 days

-4.7%

Last 30 days

-18.8%

Last 90 days

71.8%

Trailing 12 Months

-47.9%

How does ANVS drawdown profile look like?

ANVS Financial Health

Current Ratio

2.87

ANVS Investor Care

Shares Dilution (1Y)

25.70%

Diluted EPS (TTM)

-4.83

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2021877.3K597.1K316.9K36.8K
2020840.7K946.3K1.1M1.2M
2019000735.1K

Tracking the Latest Insider Buys and Sells of Annovis Bio Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 20, 2023
mccarthy reid
acquired
-
-
-
-
Nov 20, 2023
hoffman michael b
acquired
1,000,000
6.07
164,745
-
Nov 20, 2023
maccecchini maria-luisa
acquired
249,999
6.07
41,186
president and ceo
Nov 20, 2023
bruck claudine
acquired
6,070
6.07
1,000
-
Nov 20, 2023
white mark k.
acquired
12,140
6.07
2,000
-
Nov 20, 2023
hagopian henry iii
acquired
5,001
6.07
824
chief financial officer
Nov 20, 2023
mccarthy reid
acquired
5,001
6.07
824
-
Nov 20, 2023
hoffman michael b
acquired
999,668
6.1
163,880
-
Nov 20, 2023
bruck claudine
acquired
-
-
-
-
Nov 20, 2023
maccecchini maria-luisa
acquired
249,917
6.1
40,970
president and ceo

1–10 of 43

Which funds bought or sold ANVS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
223,821
223,821
-%
Feb 14, 2024
BANK OF AMERICA CORP /DE/
added
1,746
59,451
61,131
-%
Feb 14, 2024
Royal Bank of Canada
unchanged
-
1,000
1,000
-%
Feb 14, 2024
VANGUARD GROUP INC
added
30.49
3,855,070
6,308,520
-%
Feb 14, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
unchanged
-
217,356
441,320
0.01%
Feb 14, 2024
ADAGE CAPITAL PARTNERS GP, L.L.C.
reduced
-4.88
2,488,990
5,335,990
0.01%
Feb 14, 2024
MARSHALL WACE, LLP
new
-
609,284
609,284
-%

1–10 of 39

Are Funds Buying or Selling ANVS?

Are funds buying ANVS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ANVS
No. of Funds

Unveiling Annovis Bio Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Nov 28, 2023
hirschman orin
4.24%
435,000
SC 13G/A
Nov 08, 2023
hirschman orin
5.4%
548,941
SC 13G
Jan 28, 2021
hirschman orin
4.26%
293,358
SC 13G/A
Jul 21, 2020
hirschman orin
7.27%
463,797
SC 13G
Jul 10, 2020
hirschman orin
4.23%
288,290
SC 13G/A
Apr 20, 2020
maccecchini maria-luisa
19.4%
1,414,489
SC 13D
Jan 30, 2020
hirschman orin
7.36%
480,000
SC 13G

Recent SEC filings of Annovis Bio Inc

View All Filings
Date Filed Form Type Document
Feb 12, 2024
S-3/A
S-3/A
Feb 12, 2024
EFFECT
EFFECT
Feb 01, 2024
S-3
S-3
Nov 28, 2023
SC 13G/A
Major Ownership Report
Nov 22, 2023
4/A
Insider Trading
Nov 22, 2023
4/A
Insider Trading
Nov 22, 2023
4/A
Insider Trading
Nov 22, 2023
4/A
Insider Trading
Nov 22, 2023
4/A
Insider Trading
Nov 22, 2023
4/A
Insider Trading

Peers (Alternatives to Annovis Bio Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
33.2B
9.1B
-16.59% -47.80%
-9.57
3.64
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
18.9B
1.8B
-23.99% -31.71%
-42.82
10.31
76.23% 61.08%
16.7B
2.3B
-4.89% -18.90%
113.61
7.23
15.05% 75.21%
13.2B
3.7B
-7.62% -26.87%
22.1
3.57
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.27
29.46
141.38% 4.43%
6.3B
107.9M
-3.85% 226.12%
-10.03
54.1
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-19.02
17.18
-35.86% -26.24%
3.6B
240.7M
-19.08% -10.99%
-12.2
15.04
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.7
4.22
81.69% -7.29%
490.6M
1.0B
-9.17% -57.89%
-0.89
0.47
-43.15% 58.48%
185.9M
4.9M
-14.18% -58.18%
-1.13
38.02
-57.57% 50.48%
103.1M
881.7K
289.54% 381.25%
-2.17
112.79
-77.61% -13.74%
4.4M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Annovis Bio Inc News

Latest updates
MarketBeat16 Feb 202405:32 pm
InvestorsObserver15 Feb 202411:54 am

Annovis Bio Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Revenue---7,414106,131204,847586,903208,261157,438-
Operating Expenses107.4%5,920,0912,853,7702,534,1503,229,2101,909,6731,603,7572,543,629583,162870,962
  S&GA Expenses106.1%3,035,9461,472,969709,648839,627497,470884,8591,687,151516,716108,780
  R&D Expenses108.9%2,884,1451,380,8011,824,5022,389,5831,412,203718,898856,47866,446762,182
EBITDA Margin-1115.5%-394-32.43-14.13-9.37-4.72----
Income Taxes----------
Earnings Before Taxes-107.7%-5,914,641-2,848,216-2,524,602-3,199,673-1,704,613-1,006,354-2,309,490-441,590-201,256
EBT Margin-1115.5%-394-32.43-14.13-9.37-4.72----
Net Income-107.7%-5,914,641-2,848,216-2,524,602-3,199,673-1,704,613-1,006,354-2,309,490-441,590-201,256
Net Income Margin-1115.5%-394-32.43-14.13-9.37-4.72----
Free Cashflow-1.5%-1,769,320-1,743,408-3,144,563-2,474,868-765,949----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Assets-55.2%10.0023.0026.0036.0037.0040.0044.0046.0048.0049.006.008.009.0010.0011.001.00
  Current Assets-55.2%10.0023.0026.0036.0037.0040.0044.0046.0048.0049.006.008.009.0010.0011.001.00
    Cash Equivalents-59.6%6.0016.0017.0028.0032.0036.0043.0046.0047.0049.006.008.009.0010.0011.000.00
Liabilities71.9%4.002.005.008.003.001.001.002.001.001.002.001.000.001.001.003.00
  Current Liabilities71.9%4.002.005.008.003.001.001.002.001.001.002.001.000.001.001.002.00
Shareholder's Equity-67.9%7.0021.0020.0028.0035.0039.0043.0044.0047.0049.004.008.009.009.0011.000.00
  Retained Earnings-20.1%-88.05-73.33-63.79-54.05-46.33-39.90-33.96-28.73-22.81-19.96-17.44-14.24-12.53-11.53-9.22-8.78
  Additional Paid-In Capital0.7%95.0094.0084.0082.0081.0079.0077.0073.0069.0069.0022.0022.0022.0021.0020.000.00
Shares Outstanding0%9.009.008.008.008.008.008.008.008.007.007.007.00----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations2.5%-9,369-9,606-11,626-3,609-3,987-6,694-3,021-1,769-1,743-3,144-2,474-765-922-1,311-970-52.53-44.68-150-228
  Share Based Compensation-59.8%6321,5711,5421,4582,3561,9043,4353,8807868.0024.001256291,111--376*--9.00
Cashflow From Financing-100.0%-8,5727.00---5.00--25.4646,7663.00---45.3912,089-1.86-3.62-81.43530

ANVS Income Statement

2023-09-30
Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:        
Research and development$ 13,837,650  $ 4,123,538  $ 29,885,874$ 10,307,142
General and administrative1,025,621  2,361,299  4,706,8137,403,817
Total operating expenses14,863,271  6,484,837  34,592,68717,710,959
Operating loss(14,863,271)  (6,484,837)  (34,592,687)(17,710,959)
Other income:        
Interest income, net146,655  52,886  601,768108,559
Total other income146,655  52,886  601,768108,559
Loss before income taxes(14,716,616)  (6,431,951)  (33,990,919)(17,602,400)
Income tax expense (benefit)0  0  00
Net loss$ (14,716,616)$ (9,537,122)$ (9,737,181)$ (6,431,951)$ (5,936,386)$ (5,234,063)$ (33,990,919)$ (17,602,400)
Basic loss per common share$ (1.63)  $ (0.79)  $ (3.90)$ (2.16)
Diluted loss per common share$ (1.63)  $ (0.79)  $ (3.90)$ (2.16)
Weighted average number of common shares outstanding, basic9,012,273  8,163,923  8,722,5188,161,787
Weighted average number of common shares outstanding, diluted9,012,273  8,163,923  8,722,5188,161,787

ANVS Balance Sheet

2023-09-30
Balance Sheets - USD ($)
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2021
Current assets:        
Cash and cash equivalents$ 6,354,942  $ 28,377,693$ 31,987,091   
Prepaid expenses and other current assets3,868,164  7,644,3765,131,337   
Total current assets10,223,106  36,022,06937,118,428   
Total assets10,223,106  36,022,06937,118,428   
Current liabilities:        
Accounts payable1,926,397  3,961,2541,845,705   
Accrued expenses1,638,499  3,737,285680,830   
Total current liabilities3,564,896  7,698,5392,526,535   
Total liabilities3,564,896  7,698,5392,526,535   
Commitments and contingencies (Note 7)     
Stockholders' equity:        
Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding     
Common stock - $0.0001 par value, 70,000,000 and 35,000,000 shares authorized and 9,012,273 and 8,163,923 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively902  816816   
Additional paid-in capital94,703,001  82,377,48880,919,684   
Accumulated deficit(88,045,693)  (54,054,774)(46,328,607)   
Total stockholders' equity6,658,210$ 20,742,635$ 20,136,07328,323,53034,591,893$ 38,667,833$ 42,700,458$ 44,494,964
Total liabilities and stockholders' equity$ 10,223,106  $ 36,022,069$ 37,118,428   
ANVS
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
 CEO
 WEBSITEwww.annovisbio.com
 EMPLOYEES5

Annovis Bio Inc Frequently Asked Questions


What is the ticker symbol for Annovis Bio Inc? What does ANVS stand for in stocks?

ANVS is the stock ticker symbol of Annovis Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Annovis Bio Inc (ANVS)?

As of Tue Feb 20 2024, market cap of Annovis Bio Inc is 103.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANVS stock?

You can check ANVS's fair value in chart for subscribers.

What is the fair value of ANVS stock?

You can check ANVS's fair value in chart for subscribers. The fair value of Annovis Bio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Annovis Bio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANVS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Annovis Bio Inc a good stock to buy?

The fair value guage provides a quick view whether ANVS is over valued or under valued. Whether Annovis Bio Inc is cheap or expensive depends on the assumptions which impact Annovis Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANVS.

What is Annovis Bio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Feb 20 2024, ANVS's PE ratio (Price to Earnings) is -2.47 and Price to Sales (PS) ratio is 2.82 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANVS PE ratio will change depending on the future growth rate expectations of investors.